Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / S•• S•••••••

S•• S••••••• Announces Investment from A••••• Capital Partners

Platform acquisitionannouncedannounced Dec 21, 2020Fact
What happened
Target
S•• S•••••••
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
healthcare / healthcare, life sciences
Target location
NJ, US
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
11 named
Buy side
  • S•••• K••••••Board appointeeconfirmed
    “In conjunction with A•••••’s investment, S•••• K•••••• will join S•• S•••••••’s Board of Directors.”
  • S•••• K••••••Board appointeeconfirmed
    “In conjunction with A•••••’s investment, S•••• K•••••• will join S•• S•••••••’s Board of Directors.”
  • N••• A••••••Deal partnerconfirmed
    “N••• A••••••, Partner of A••••• stated, “Through our multiple investments in Life Sciences Services, we have experienced firsthand the exciting opportunity around emerging biotechs.”
  • A••••• C•••••• P•••••••• L•••Sponsorconfirmed
    “S•• S••••••• Holdings LLC (“S•• S•••••••” or the “Company”), a leading Life Sciences consultancy, announced today that it has received a growth investment from A••••• Capital Partners, LP (“A•••••”), a middle-market private equity firm focused exclusively on the Healthcare sector.”
Financing side
Advisory side
  • I•••••••• A•••••••Sell-side adviserconfirmed
    “I•••••••• A••••••• acted as exclusive financial advisor to S•• S•••••••, and Golenbock, Eiseman, Assor, Bell & Peskoe LLP provided legal counsel.”
  • I•••••••• A•••••••Sell-side adviserconfirmed
    “I•••••••• A••••••• acted as exclusive financial advisor to S•• S•••••••, and Golenbock, Eiseman, Assor, Bell & Peskoe LLP provided legal counsel.”
Side not stated
  • D•••••• L••••Managementconfirmed
    “D•••••• L••••, CEO of S•• S•••••••, stated, “We will also establish a Gene Therapy Accelerator to enable the rapid expansion of early-stage companies through the combination of direct investment and our industry-leading consulting capabilities.”
  • A••• S•••••••Managementconfirmed
    “A••• S•••••••, President of S•• S••••••• said, “The partnership with A••••• will fuel S•• S•••••••’s growth into adjacent business functions and reinforce our position as an industry-leading consulting firm focused on the full lifecycle of Life Sciences organizations.””
  • D•••••• L••••Managementconfirmed
    “D•••••• L••••, CEO of S•• S•••••••, stated, “We will also establish a Gene Therapy Accelerator to enable the rapid expansion of early-stage companies through the combination of direct investment and our industry-leading consulting capabilities.”
  • S•• S•••••••Targetconfirmed
    “S•• S••••••• Announces Investment from A••••• Capital Partners”
Evidence
“S•• S••••••• Announces Investment from A••••• Capital Partners”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 16, 2026